Sysop: 1 revision imported

2025-11-01T14:26:56Z

1 revision imported

← Older revision	Revision as of 14:26, 1 November 2025
(No difference)

en>Nova64: Add link to MXE page

2024-08-29T00:14:40Z

Add link to MXE page

New page

{{stub}}
[[File:Substituted diarylethylamine.svg|250px|thumbnail|General chemical structure of a diarylethylamine]]
'''Diarylethylamines''' are a chemical class of [[psychoactive substances]] that produce [[dissociative]] effects when [[administered]]. [[Subjective effects]] are similar to those of [[arylcyclohexylamine]] dissociatives like [[PCP]] or [[ketamine]], although they differ in their chemical structure.

Diarylethylamines are examples of contemporary designer drugs specifically chosen to mimic and/or replace the functional and structural features of commonly used illicit substances. They have been marketed on the online research chemicals market as a replacement for [[MXE]] and other dissociatives.

Very little is known about the human pharmacology, metabolism, and toxicity of these compounds. Many reports suggest that they may pose different and more pronounced risks than traditional dissociatives.

===Pharmacology===
{| class="wikitable mw-collapsible" width="50%"
|-
|+NMDAR binding affinities for five target 1,2-diphenylethylamines and reference compounds<ref name="Pharma2016">{{cite journal | journal=PLOS ONE | title=Pharmacological Investigations of the Dissociative ‘Legal Highs’ Diphenidine, Methoxphenidine and Analogues | volume=11 | issue=6 | pages=e0157021 | date=17 June 2016 | url=https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0157021 | issn=1932-6203 | doi=10.1371/journal.pone.0157021}}</ref>
|-
!Compound
!IC50 ± SEM (nM)
!Ki ± SEM (nM)
|-
|[[PCP]]<ref>{{cite journal | vauthors=((Wallach, J.)) | journal=UNIVERSITY OF THE SCIENCES IN PHILADELPHIA | title=Structure activity relationship (SAR) studies of arylcycloalkylamines as N-methyl-D-aspartate receptor antagonists | pages=626 | date= 2014 | url=https://www.semanticscholar.org/paper/Structure-activity-relationship-(SAR)-studies-of-as-Wallach/cc0f16999e363db74bd501f5a041083f6b0f6b5a}}</ref>
|91 ± 1.3
|57.9 ± 0.8
|-
|[[Ketamine]]
|508.5 ± 30.1
|323.9 ± 19.2
|-
|[[Memantine]]
|594.2 ± 41.3
|378.4 ± 26.3
|-
|(+)-[[MK-801]]
|4.1 ± 1.6
|2.5 ± 1.0
|-
|[[Diphenidine]]*
|28.6 ± 3.5
|18.2 ± 2.2
|-
|2-MXP ([[Methoxphenidine]])
|56.5 ± 5.8
|36.0 ± 3.7
|-
|3-MXP
|30.3 ± 2.6
|19.3 ± 1.7
|-
|4-MXP
|723.8 ± 69.9
|461.0 ± 44.5
|-
|2-Cl-Diphenidine*
|14.6 ± 2.1
|9.3 ± 1.3
|-
| colspan="3" style="text-align:center;" |NMDAR binding affinites determined using [3H]-(+)-MK-801 in rat forebrain.<ref name="Pharma2016" />

*Diphenidine is sometimes referred to as DPH in scientific studies despite this name already being in common use and widely accepted as meaning [[diphenhydramine]], an unrelated substance.
|}

{| class="wikitable mw-collapsible" width="70%"
|-
|+Inhibition potencies of 1,2-diarylethylamines as monoamine transporter reuptake inhibitors.<ref name="Pharma2016" />
|-
| colspan="4" style="text-align:center;" |IC50 ± SEM (μM)
|-
!Compound
!DAT
!NET
!SERT
|-
|DPH ([[Diphenidine]])
|1.99 (0.91)
|9.25 (0.97)
|>10 μM
|-
|2-MXP ([[Methoxphenidine]])
|30.0 (0.81)
|35.2 (2.04)
|>10 μM
|-
|[[3-MXP]]
|0.587 (0.92)
|2.71 (0.95)
|>10 μM
|-
|[[4-MXP]]
|2.23 (0.96)
|22.5 (1.75)
|19.0 (1.12)
|-
|[[2-Cl-DPH]]
|10.5 (0.65)
|27.1 (1.02)
|>10 μM
|-
| colspan="4" style="text-align:left;" |IC50 values shown in μM. Hill slopes shown in parenthesis. ND-IC50 values were not determined because compounds showed less than 50% inhibition of uptake at 10 μM during a preliminary screening.
Inhibition potencies of 1,2-diarylethylamines as monoamine transporter reuptake inhibitors.<ref name="Pharma2016" />
|}

==List of substituted diarylethylamines==
{| class="wikitable"
|-
! scope="col" |'''Compound'''
! scope="col" style="width: 50px;" |'''RN1'''
! scope="col" style="width: 50px;" |'''RN2'''
! scope="col" style="width: 50px;" |'''R2'''
! scope="col" |'''Structure'''
|-
|[[Ephenidine]]||CH2CH3||H||H||[[File:Ephenidine.svg|170px]]
|-
|[[Diphenidine]]||CH2CH2CH2-||CH2CH2-||H||[[File:Diphenidine.svg|170px]]
|-
|[[Methoxphenidine]]||CH2CH2CH2-||CH2CH2-||OCH3||[[File:Methoxphenidine.svg|170px]]
|-
|}

==See also==

*[[Responsible use]]
*[[Dissociative]]
*[[Arylcyclohexylamine]]

==Literature==

*Wallach, J., Kang, H., Colestock, T., Morris, H., Bortolotto, Z. A., Collingridge, G. L., ... & Adejare, A. (2016). Pharmacological investigations of the dissociative ‘legal highs’ diphenidine, methoxphenidine and analogues. PLoS One, 11(6), e0157021. https://doi.org/10.1371/journal.pone.0157021
*Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620
*Wallach, J., & Brandt, S. D. (2018). 1, 2-Diarylethylamine-and Ketamine-Based New Psychoactive Substances. In New Psychoactive Substances (pp. 305-352). Springer, Cham. http://dx.doi.org/10.1007/164_2018_148

==References==
<references />

[[Category:Chemical class]]
[[Category:Diarylethylamine|*]]

Diarylethylamines - Revision history

Sysop: 1 revision imported

en>Nova64: Add link to MXE page